- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02153944
Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety
Cognitive vs. Emotional Psycho-Pharmacological Manipulations of Fear vs. Anxiety
Objective:
The overall aim of this protocol is to examine the effect of pharmacological manipulations of affective and cognitive processes on anxiety and task performance. Ultimately, the goal is 1) to provide insight into the relative influence of cognitive and affective states on anxiety, 2) generate theoretical models that can be applied to a better understanding of the interaction between cognition and emotion, 3) develop a better screening approach to candidate anxiolytics, and 4) help formulate novel therapeutic interventions for clinical anxiety.
Excessive or inappropriately sustained anxiety and fear lead to the most common group of psychiatric disorders. A number of theoretical models have been proposed to understand the mechanisms engaged in these maladaptive behaviors. Most recent emphasis has focused on the synergistic contribution of cognitive and emotional processes. Our laboratory has been instrumental in delineating aspects of behavioral and neural processes that are associated with fear and anxiety, using psychophysiological and neuroimaging measures of fear and anxiety. Evidence shows that levels of anxiety modulate cognitive performance, such as working memory or perceptual discrimination, and that, conversely, cognitive engagement influences severity of experimentally induced anxiety. The exact contribution of emotional processes vs. cognitive processes to the experience of anxiety is not clear, similarly to the neural mechanisms underlying these interactions.
In this protocol, we propose to manipulate pharmacologically separately cognitive and emotional processes to dissociate their contribution to fear/anxiety, while using state-of-the-art measures of anxiety derived from translational work. Indeed, we already developed integrative experimental models of fear and anxiety via the manipulation of predictable and unpredictable shock, respectively. We already employed successfully these models to measure anxiolytic and anxiogenic effects of various compounds such as alprazolam, citalopram, hydrocortisone, and oxytocin in healthy participants.
We propose in a first step (step-1) to start with a simple proof-of-concept study, using two pharmacological compounds in a double-blind randomized parallel design, each preferentially acting respectively on the cognitive (methylphenidate) or affective (propranolol) domain, and using a single cognitive process (working memory). In a second step (step-2), we propose to extend this work to the fMRI to examine the cognitive correlates of the effects seen in the step-1 behavioral study, specifically with methylphenidate. Whereas the comparison among three drugs is planned for the electrophysiology study, we plan to study only the drug that improves cognition in the fMRI. The reason we will focus on methylphenidate in step 2 is that our overall goal is to study the effect of improving cognitive functions on anxiety using neuroimaging. To reach this goal, we plan to use different approaches to boost cognitive functions in the coming years, including psychopharmacology, direct current stimulation, mindfulness. Methylphenidate is our first psychopharmacological study towards this objective. Future work will also expand to other compounds and cognitive processes, as well as vary the strategy to induce anxiety. Presently, anxiety will be induced using the threat of shock, while participants perform the task. We will examine in step-1 whether 1) the reduction of induced-anxiety with propranolol improves cognitive performance, and 2) the facilitation of cognitive performance with methylphenidate reduces induced-anxiety. In step-2, we will identify the neural mechanisms underlying the effects of methylphenidate, the drug having beneficial effects on cognitive function.
Study population:
Medically and psychiatrically healthy adult males and females, aged 18 to 50 years.
Design:
The study is a double-blind design. For step-1, three groups of healthy participants will come for one experimental session. During this session, they will be asked to perform a working memory task under the threat of shock, i.e., while anticipating unpleasant electric shocks. Each group will receive one drug challenge, either placebo, propranolol (40 g) or methylphenidate (20 mg). For step-2, the study tasks will be conducted in a 3T fMRI scanner. In this step, only methylphenidate and placebo will be compared. Two groups will come for one experimental session, one will receive placebo and the other one will receive methylphenidate (20 mg). In a follow-up study for the step-2 fMRI the two groups will come for one experimental fMRI session one will receive methylphenidate (60 mg).
Outcome measures:
In step-1, the primary outcome measures are the startle reflex and performance on the working memory task. In step-2, the primary outcome measures are the startle reflex and the cerebral fMRI blood-oxygen-level ...
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective:
The overall aim of this protocol is to examine the effect of pharmacological manipulations of affective and cognitive processes on anxiety and task performance. Ultimately, the goal is 1) to provide insight into the relative influence of cognitive and affective states on anxiety, 2) generate theoretical models that can be applied to a better understanding of the interaction between cognition and emotion, 3) develop a better screening approach to candidate anxiolytics, and 4) help formulate novel therapeutic interventions for clinical anxiety.
Excessive or inappropriately sustained anxiety and fear lead to the most common group of psychiatric disorders. A number of theoretical models have been proposed to understand the mechanisms engaged in these maladaptive behaviors. Most recent emphasis has focused on the synergistic contribution of cognitive and emotional processes. Our laboratory has been instrumental in delineating aspects of behavioral and neural processes that are associated with fear and anxiety, using psychophysiological and neuroimaging measures of fear and anxiety. Evidence shows that levels of anxiety modulate cognitive performance, such as working memory or perceptual discrimination, and that, conversely, cognitive engagement influences severity of experimentally induced anxiety. The exact contribution of emotional processes vs. cognitive processes to the experience of anxiety is not clear, similarly to the neural mechanisms underlying these interactions.
In this protocol, we propose to manipulate pharmacologically separately cognitive and emotional processes to dissociate their contribution to fear/anxiety, while using state-of-the-art measures of anxiety derived from translational work. Indeed, we already developed integrative experimental models of fear and anxiety via the manipulation of predictable and unpredictable shock, respectively. We already employed successfully these models to measure anxiolytic and anxiogenic effects of various compounds such as alprazolam, citalopram, hydrocortisone, and oxytocin in healthy participants.
We propose in a first step (step-1) to start with a simple proof-of-concept study, using two pharmacological compounds in a double-blind randomized parallel design, each preferentially acting respectively on the cognitive (methylphenidate) or affective (propranolol) domain, and using a single cognitive process (working memory). In a second step (step-2), we propose to extend this work to the fMRI to examine the cognitive correlates of the effects seen in the step-1 behavioral study, specifically with methylphenidate. Whereas the comparison among three drugs is planned for the electrophysiology study, we plan to study only the drug that improves cognition in the fMRI. The reason we will focus on methylphenidate in step 2 is that our overall goal is to study the effect of improving cognitive functions on anxiety using neuroimaging. To reach this goal, we plan to use different approaches to boost cognitive functions in the coming years, including psychopharmacology, direct current stimulation, mindfulness. Methylphenidate is our first psychopharmacological study towards this objective. Future work will also expand to other compounds and cognitive processes, as well as vary the strategy to induce anxiety. Presently, anxiety will be induced using the threat of shock, while participants perform the task. We will examine in step-1 whether 1) the reduction of induced-anxiety with propranolol improves cognitive performance, and 2) the facilitation of cognitive performance with methylphenidate reduces induced-anxiety. In step-2, we will identify the neural mechanisms underlying the effects of methylphenidate, the drug having beneficial effects on cognitive function.
Study population:
Medically and psychiatrically healthy adult males and females, aged 18 to 50 years.
Design:
The study is a double-blind design. For step-1, three groups of healthy participants will come for one experimental session. During this session, they will be asked to perform a working memory task under the threat of shock, i.e., while anticipating unpleasant electric shocks. Each group will receive one drug challenge, either placebo, propranolol (40 g) or methylphenidate (20 mg). For step-2, the study tasks will be conducted in a 3T fMRI scanner. In this step, only methylphenidate and placebo will be compared. Two groups will come for one experimental session, one will receive placebo and the other one will receive methylphenidate (20 mg). In a follow-up study for the step-2 fMRI the two groups will come for one experimental fMRI session one will receive methylphenidate (60 mg).
Outcome measures:
In step-1, the primary outcome measures are the startle reflex and performance on the working memory task. In step-2, the primary outcome measures are the startle reflex and the cerebral fMRI blood-oxygen-level dependent (BOLD) responses. For both step-1 and step-2, secondary measures include skin conductance, heart rate, and subjective measures of anxiety.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
- INCLUSION CRITERIA:
- Ages 18-50
- Males and females
- Subjects give their own consent
EXCLUSION CRITERIA:
- Clinically significant prior exposure to medications, that based on the investigator s judgment, may impact the study, such as Ritalin (MPH).
- Any significant medical or neurological problems (e.g. cardiovascular illness, respiratory illness, neurologic illness, seizure, etc.)
- Raynaud syndrome
- IQ < 80
- Sinus bradycardia (P<45), or tachycardia (P>90)
- Significant ECG abnormality (i.e., greater than first-degree block etc.) as determined by investigators judgement
- High or low blood pressure (SBP>140 or SBP<90; SDP<50 or SDP>90)
- A first-degree family history of mania, schizophrenia, or other psychoses based on verbal reports
- Significant past psychopathology (e.g., hospitalization for psychiatric disorders, recurrent depression, suicide attempt, psychoses)
- Current psychiatric disorders according to Diagnostic and Statistical Manual (DSM)-V
- Current alcohol or substance use disorder
- Current use of psychotropic medication
- Impaired hearing (clinic study only)
- Pregnancy or positive pregnancy test
- Neurological syndrome of the wrist (e.g., carpal tunnel syndrome) for shocks to be delivered on affected arm.
- Breastfeeding
- Significant lab abnormalities (i.e., complete blood count (CBC) with differential, acute care and mineral panel, hepatic panel, TSH)
- Positive urine toxicology screen
- You have been in another study with an experimental medication within the previous month
- For physiological/clinic participants: small startle reactivity (a change in EMG activity that is less than 3 times the baseline EMG activity)
- Current daily use of anti-acid -medication or within 5 half-lives of study visit if taken on pro re nata (PRN) basis
- Employee of National Institute of Mental Health (NIMH) or an immediate family member who is a NIMH employee.
For functional magnetic resonance imaging (fMRI) participants: Any medical condition that increases risk for fMRI:
- Any metal implants (clips, screws, plates, pins, etc.) that are not safe for MRI or metal fragments cause by injuries or metal working. Metal implants that are deemed MRI safe are allowable (i.e. certain screws).
- Any sort of medical implants that are not safe for the MRI (aneurysm clips, pacemaker, insulin pump, Hickman line, etc.). Medical implants that are MRI safe (Nexplanon implant, certain intrauterine device (IUDs), etc.) are allowable.
- Permanent eye liner and tattoos above the neck
- Patients who have difficulty lying flat on their back for up to 90 min in the scanner
- Participants who are uncomfortable in small closed spaces (have claustrophobia) and would feel uncomfortable in the MRI machine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Behavioral: Drug challenge with methylphenidate
Participant received methylphenidate 20 mg orally during study visit
|
Methylphenidate 20mg was given orally during study visit
|
Placebo Comparator: Behavioral: Drug challenge with placebo
Participant received placebo orally during study visit
|
Placebo was given orally during study visit
|
Experimental: Behavioral: Drug challenge with propranolol
Participants received propranolol 40mg orally during study visit
|
Propranolol 40 mg was given orally during study visit
|
Experimental: fMRI: Drug challenge with methylphenidate
Participant received methylphenidate 20 mg orally during study visit
|
Methylphenidate 20mg was given orally during study visit
|
Placebo Comparator: fMRI: Drug challenge with placebo
Participant received placebo orally during study visit
|
Placebo was given orally during study visit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Magnitude of Startle Reflex During Safe Condition
Time Frame: 20-120 milliseconds following the onset of the startle stimulus
|
The magnitude of the startle reflex during working memory tasks (n-back) while undergoing alternating periods of safety and threat of shock.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
The participant holds each stimulus in short-term memory while new stimuli are presented.
For each new item presented, the participant's task is to decide if it is the same as the stimulus presented one time before (1Back), two times before (2Back) or three times before (3Back) by responding "yes" if the stimulus currently presented matches the stimulus presented earlier.
Participants responded with a button press.
The startle reflex was elicited with a 102 decibel (dB) white noise (40-ms duration) delivered via headphone.
The eyeblink component of the startle reflex was recorded binaurally with two silver chloride (AgCl) electrodes placed under one eye.
|
20-120 milliseconds following the onset of the startle stimulus
|
Magnitude of Startle Reflex During Threat Condition
Time Frame: 20-120 milliseconds following the onset of the startle stimulus
|
The magnitude of the startle reflex during working memory tasks (n-back) while undergoing alternating periods of safety and threat of shock.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
The participant holds each stimulus in short-term memory while new stimuli are presented.
For each new item presented, the participant's task is to decide if it is the same as the stimulus presented one time before (1Back), two times before (2Back) or three times before (3Back) by responding "yes" if the stimulus currently presented matches the stimulus presented earlier.
Participants responded with a button press.
The startle reflex was elicited with a 102 decibel (dB) white noise (40-ms duration) delivered via headphone.
The eyeblink component of the startle reflex was recorded binaurally with two silver chloride (AgCl) electrodes placed under one eye.
|
20-120 milliseconds following the onset of the startle stimulus
|
Proportion of Correct Responses in the Working Memory Task (N-back) - Safe Condition
Time Frame: Task started 90 minutes post drug admin up to max of 125 mins post drug admin (max total is 35 mins) during a 6-hour single day visit
|
Stimuli were presented one at a time on a screen.
Participants were instructed to remember (working memory) one, two, or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe).
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
The participant holds each stimulus in short-term memory while new stimuli are presented.
For each new item presented, the participant's task is to decide if it is the same as the stimulus presented one time before (1Back), two times before (2Back) or three times before (3Back)" by responding "yes" if the stimulus currently presented matches the stimulus presented earlier.
Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1Back, 2Back, 3Back) using repeated measures ANOVA.
|
Task started 90 minutes post drug admin up to max of 125 mins post drug admin (max total is 35 mins) during a 6-hour single day visit
|
Proportion of Correct Responses in the Working Memory Task (N-back) - Threat Condition
Time Frame: task started 90 minutes post drug admin up to max of 125 mins post drug admin (max total is 35 mins) during a 6-hour single day visit
|
Stimuli were presented one at a time on a screen.
Participants were instructed to remember (working memory) one, two, or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe).
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
The participant holds each stimulus in short-term memory while new stimuli are presented.
For each new item presented, the participant's task is to decide if it is the same as the stimulus presented one time before (1Back), two times before (2Back) or three times before (3Back)" by responding "yes" if the stimulus currently presented matches the stimulus presented earlier.
Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1Back, 2Back, 3Back) using repeated measures ANOVA.
|
task started 90 minutes post drug admin up to max of 125 mins post drug admin (max total is 35 mins) during a 6-hour single day visit
|
Proportion of Correct Responses in the Working Memory Task (N-Back): Safe Condition - 1BACK - Run 1
Time Frame: 90 minutes post drug admin plus zero seconds within a 6-hour study visit
|
Stimuli were presented one at a time on a screen.
Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe).Two levels of difficulties were tested: 1- and 3-back.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block represented a given level of difficulty, i.e., 1- and 3-back.
Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA.
|
90 minutes post drug admin plus zero seconds within a 6-hour study visit
|
Proportion of Correct Responses in the Working Memory Task (N-back): Threat Condition - 1BACK - Run 1
Time Frame: 90 minutes plus 90 seconds within a 6-hour study visit
|
Stimuli were presented one at a time on a screen.
Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe).
Two levels of difficulties were tested: 1- and 3-back.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block represented a given level of difficulty, i.e., 1- and 3-back.
Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA.
|
90 minutes plus 90 seconds within a 6-hour study visit
|
Proportion of Correct Responses in the Working Memory Task (N-back): Safe Condition - 1BACK - Run 2
Time Frame: 90 minutes plus 180 seconds within a 6-hour study visit
|
Stimuli were presented one at a time on a screen.
Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe).
Two levels of difficulties were tested: 1- and 3-back.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block represented a given level of difficulty, i.e., 1- and 3-back.
Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA.
|
90 minutes plus 180 seconds within a 6-hour study visit
|
Proportion of Correct Responses in the Working Memory Task (N-back): Threat Condition - 1BACK - Run 2
Time Frame: 90 minutes plus 260 seconds within a 6-hour study visit
|
Stimuli were presented one at a time on a screen.
Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe).
Two levels of difficulties were tested: 1- and 3-back.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block represented a given level of difficulty, i.e., 1- and 3-back.
Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA.
|
90 minutes plus 260 seconds within a 6-hour study visit
|
Proportion of Correct Responses in the Working Memory Task (N-back): Safe Condition - 3BACK - Run 1
Time Frame: 90 minutes post drug admin plus 45 seconds within a 6-hour study visit
|
Stimuli were presented one at a time on a screen.
Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe).
Two levels of difficulties were tested: 1- and 3-back.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block represented a given level of difficulty, i.e., 1- and 3-back.
Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA.
|
90 minutes post drug admin plus 45 seconds within a 6-hour study visit
|
Proportion of Correct Responses in the Working Memory Task (N-back): Threat Condition - 3BACK - Run 1
Time Frame: 90 minutes plus 135 seconds within a 6-hour study visit
|
Stimuli were presented one at a time on a screen.
Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe).
Two levels of difficulties were tested: 1- and 3-back.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block represented a given level of difficulty, i.e., 1- and 3-back.
Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA.
|
90 minutes plus 135 seconds within a 6-hour study visit
|
Proportion of Correct Responses in the Working Memory Task (N-back): Safe Condition - 3BACK - Run 2
Time Frame: 90 minutes plus 215 seconds within a 6-hour study visit
|
Stimuli were presented one at a time on a screen.
Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe).
Two levels of difficulties were tested: 1- and 3-back.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block represented a given level of difficulty, i.e., 1- and 3-back.
Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA.
|
90 minutes plus 215 seconds within a 6-hour study visit
|
Proportion of Correct Responses in the Working Memory Task (N-back): Threat Condition - 3BACK - Run 2
Time Frame: 90 minutes plus 305 seconds within a 6-hour study visit
|
Stimuli were presented one at a time on a screen.
Participants were instructed to remember (working memory) one or three stimuli back (N-back) from the current stimulus on the screen while undergoing alternating periods of safety and threat of shock i.e. while anticipating unpleasant electric shocks or no shock (safe).
Two levels of difficulties were tested: 1- and 3-back.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Participants indicated whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task included 3 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block represented a given level of difficulty, i.e., 1- and 3-back.
Performance on working memory task (n-back) accuracy was measured across condition (threat and safe) x Load (1-back, 3-back) using repeated measures ANOVA.
|
90 minutes plus 305 seconds within a 6-hour study visit
|
Reaction Time to Stimuli: Safe Condition - 1BACK - Run 1
Time Frame: 90 minutes post drug admin plus zero seconds within a 6-hour study visit
|
Reaction time (RT) is the time it takes to respond to stimuli.
Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Two levels of difficulties were tested: 1Back and 3Back (n-back).
Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks.
RT was analyzed using condition( threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA.
|
90 minutes post drug admin plus zero seconds within a 6-hour study visit
|
Reaction Time to Stimuli: Threat Condition - 1BACK - Run 1
Time Frame: 90 minutes plus 90 seconds within a 6-hour study visit
|
Reaction time (RT) is the time it takes to respond to stimuli.
Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Two levels of difficulties were tested: 1Back and 3Back (n-back).
Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks.
RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA.
|
90 minutes plus 90 seconds within a 6-hour study visit
|
Reaction Time to Stimuli: Safe Condition - 1BACK - Run 2
Time Frame: 90 minutes plus 180 seconds within a 6-hour study visit
|
Reaction time (RT) is the time it takes to respond to stimuli.
Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Two levels of difficulties were tested: 1Back and 3Back (n-back).
Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks.
RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA.
|
90 minutes plus 180 seconds within a 6-hour study visit
|
Reaction Time to Stimuli: Threat Condition - 1BACK - Run 2
Time Frame: 90 minutes plus 260 seconds within a 6-hour study visit
|
Reaction time (RT) is the time it takes to respond to stimuli.
Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Two levels of difficulties were tested: 1Back and 3Back (n-back).
Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks.
RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA.
|
90 minutes plus 260 seconds within a 6-hour study visit
|
Reaction Time to Stimuli: Safe Condition - 3BACK - Run 1
Time Frame: 90 minutes post drug admin plus 45 seconds within a 6-hour study visit
|
Reaction time (RT) is the time it takes to respond to stimuli.
Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Two levels of difficulties were tested: 1Back and 3Back (n-back).
Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks.
RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA.
|
90 minutes post drug admin plus 45 seconds within a 6-hour study visit
|
Reaction Time to Stimuli: Threat Condition - 3BACK - Run 1
Time Frame: 90 minutes plus 135 seconds within a 6-hour study visit
|
Reaction time (RT) is the time it takes to respond to stimuli.
Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Two levels of difficulties were tested: 1Back and 3Back (n-back).
Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks.
RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA.
|
90 minutes plus 135 seconds within a 6-hour study visit
|
Reaction Time to Stimuli: Safe Condition - 3BACK - Run 2
Time Frame: 90 minutes plus 215 seconds within a 6-hour study visit
|
Reaction time (RT) is the time it takes to respond to stimuli.
Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Two levels of difficulties were tested: 1Back and 3Back (n-back).
Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks.
RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA.
|
90 minutes plus 215 seconds within a 6-hour study visit
|
Reaction Time to Stimuli: Threat Condition - 3BACK - Run 2
Time Frame: 90 minutes plus 305 seconds within a 6-hour study visit
|
Reaction time (RT) is the time it takes to respond to stimuli.
Participants RTs were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks (threat) or no shock (safe) during the n-back paradigm task.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Two levels of difficulties were tested: 1Back and 3Back (n-back).
Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
The task was organized in 2 runs, 8 blocks per run (4 safe and 4 threat presented alternatively), 18 sequential letters per block.
Each block (threat or safe) corresponded to 2 tasks, 1- and 3-back tasks.
RT was analyzed using condition (threat, safe) x Load (1Back, 3Back) repeated-measures ANOVA.
|
90 minutes plus 305 seconds within a 6-hour study visit
|
Measure of BOLD Response in Brain Clusters - Safe Condition - 1BACK
Time Frame: started 90 minutes post drug administration plus 90 seconds within a 6-hour study visit
|
The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner.
The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain blood flow and blood oxygenation in activated regions-of-interest (ROI).
Participants BOLD responses were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks or no shock (safe) during the n-back task.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Two levels of difficulties were tested: 1Back and 3Back (n-back).
Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
|
started 90 minutes post drug administration plus 90 seconds within a 6-hour study visit
|
Measure of BOLD Response in Brain Cluster - Threat Condition - 1BACK
Time Frame: started 90 minutes post drug administration plus up to 360 seconds within a 6-hour study visit
|
The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner.
The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain blood flow and blood oxygenation in activated regions-of-interest (ROI).
Participants BOLD responses were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks or no shock (safe) during the n-back task.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Two levels of difficulties were tested: 1Back and 3Back (n-back).
Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
|
started 90 minutes post drug administration plus up to 360 seconds within a 6-hour study visit
|
Measure of BOLD Response in Brain Clusters - Safe Condition - 3BACK
Time Frame: started 90 minutes post drug administration plus up to 270 seconds within a 6-hour study visit
|
The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner.
The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner.
The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain blood flow and blood oxygenation in activated regions-of-interest (ROI).
Participants BOLD responses were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks or no shock (safe) during the n-back task.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Two levels of difficulties were tested: 1Back and 3Back (n-back).
Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
|
started 90 minutes post drug administration plus up to 270 seconds within a 6-hour study visit
|
Measure of BOLD Response in Brain Cluster - Threat Condition - 3BACK
Time Frame: started 90 minutes post drug administration plus up to 450 seconds within a 6-hour study visit
|
The blood-oxygen-level dependent (BOLD) responses were measured using an fMRI scanner.
The cerebral fMRI BOLD uses magnetic fields to measure localized changes in brain blood flow and blood oxygenation in activated regions-of-interest (ROI).
Participants BOLD responses were measured while undergoing alternating periods of safety and shock threat conditions i.e. while anticipating unpleasant electric shocks or no shock (safe) during the n-back task.
The n-back is a paradigm used to assess working memory function by presenting sequential stimuli individually.
Two levels of difficulties were tested: 1Back and 3Back (n-back).
Participants were instructed to indicate whether the letter currently displayed was the same as the letter presented 1 or 3 letters back.
|
started 90 minutes post drug administration plus up to 450 seconds within a 6-hour study visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure of Level of Anxiety
Time Frame: 20 minutes after arrival for study; 80, 100, & 125 minutes post drug administration
|
The level of anxiety was assessed using the State Anxiety Inventory questionnaire.
The State Anxiety Scale (S-Anxiety) evaluates the current state of anxiety.
The State Anxiety Scale has 20 items.
All items are rated on a 4-point scale ranging from "1 = not at all" to "4 = very much so".
The scale has a minimum score of 20 and a maximum score of 80. Higher score indicates greater anxiety.
State Anxiety score was measured at different time points during the study.
|
20 minutes after arrival for study; 80, 100, & 125 minutes post drug administration
|
Measure of Level of Anxiety
Time Frame: 20 minutes after arrival for study; 10 minutes & 145 minutes post drug administration
|
The level of anxiety was assessed using the State Anxiety Inventory questionnaire.
The State Anxiety Scale (S-Anxiety) evaluates the current state of anxiety.
The State Anxiety Scale has 20 items.
All items are rated on a 4-point scale ranging from "1 = not at all" to "4 = very much so".
The scale has a minimum score of 20 and a maximum score of 80. Higher score indicates greater anxiety.
State Anxiety score was measured at different time points during the study.
|
20 minutes after arrival for study; 10 minutes & 145 minutes post drug administration
|
Measure of Heart Rate
Time Frame: 20 minutes after arrival for study; 80 minutes & 125 minutes post drug administration
|
The heart rate was monitored with two disposable electrodes on the ribcage midway between the waist and the armpit.
|
20 minutes after arrival for study; 80 minutes & 125 minutes post drug administration
|
Measure of Heart Rate
Time Frame: 20 minutes after arrival for study; 10 minutes & 145 minutes post drug administration
|
The heart rate was monitored with two disposable electrodes on the ribcage midway between the waist and the armpit.
|
20 minutes after arrival for study; 10 minutes & 145 minutes post drug administration
|
Collaborators and Investigators
Investigators
- Principal Investigator: Monique Ernst, M.D., National Institute of Mental Health (NIMH)
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Anxiety Disorders
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Propranolol
- Methylphenidate
Other Study ID Numbers
- 140114
- 14-M-0114
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety Disorder
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
University of MichiganBrain & Behavior Research FoundationNot yet recruitingGeneralized Anxiety Disorder | Anxiety | Social Anxiety Disorder | Panic DisorderUnited States
-
Baylor College of MedicineUniversity of PennsylvaniaRecruitingGeneralized Anxiety Disorder | Anxiety | Autism Spectrum Disorder | Separation Anxiety | Social Anxiety Disorder of ChildhoodUnited States
-
Erasmus Medical CenterTerminatedGeneralized Anxiety Disorder | Social Anxiety Disorder | Specific Phobia | Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood, Early OnsetNetherlands
-
Baylor College of MedicineRecruitingGeneralized Anxiety Disorder | Panic Disorder | Panic Disorder With Agoraphobia | Separation Anxiety | Anxiety Disorder of Childhood | Panic Attacks | Social Anxiety Disorder of Childhood | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Daniel LiebermanTerminatedAnxiety | Anxiety Disorder SocialUnited States
-
Hospital de Clinicas de Porto AlegreUnknownGeneralized Anxiety Disorder | Social Anxiety Disorder | Separation Anxiety DisorderUnited States, Australia, Brazil, Israel
-
UCLH/UCL Joint Research OfficeMedical Research Council; Camden and Islington NHS Trust; Central and North West...RecruitingAnxiety Disorders | Anxiety | Anxiety Depression | CBT | Anxiety Disorders and Symptoms | Anxiety Generalized | Generalised Anxiety Disorder | Anxiety Disorder; Mixed With Depression (Mild) | Anxiety Disorder GeneralizedUnited Kingdom
-
State University of New York - Upstate Medical...CompletedGeneral Anxiety Disorder, Social Anxiety DisorderUnited States
-
Haukeland University HospitalUniversity of BergenCompletedGeneralized Anxiety Disorder | Social Anxiety Disorder | Separation Anxiety DisorderNorway
Clinical Trials on Methylphenidate
-
University of ArkansasCompleted
-
Mahidol UniversityNot yet recruiting
-
Massachusetts General HospitalFood and Drug Administration (FDA); Center for Psychiatry And Behavioral Medicine...Completed
-
Florida International UniversityNational Institute of Mental Health (NIMH)CompletedAttention Deficit Disorder With HyperactivityUnited States
-
Ironshore Pharmaceuticals and Development, IncCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Boston Children's HospitalNational Institute of Mental Health (NIMH)CompletedEpilepsy | Attention Deficit Disorder With HyperactivityUnited States
-
Tehran University of Medical SciencesUnknownAttention Deficit Hyperactivity DisorderIran, Islamic Republic of
-
Children's Hospital of PhiladelphiaOrtho-McNeil Janssen Scientific Affairs, LLCCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Milton S. Hershey Medical CenterChildren's Miracle NetworkTerminatedBehavioral Insomnia of Childhood | Attention Deficit Disorder With HyperactivityUnited States
-
Massachusetts General HospitalMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.CompletedAttention Deficit Hyperactivity DisorderUnited States